Truth Tide TV UNSEALED 1419 Files · 74547 Email Threads
menu
videocam Videos headphones Audio description Documents mail Email analytics Reports article Articles auto_stories Narratives search Search
policy Investigate expand_more
inbox Inbox 74547 send Sent 28705 label All Mail 74547 attach_file Attachments 1907 topic Topics
People
Jeffrey Epstein person
Ghislaine Maxwell person
Bill Clinton person
Alan Dershowitz person
Elon Musk person
Bill Gates person
Ehud Barak person
Reid Hoffman person
Peter Thiel person
Larry Summers person
Prince Andrew person
Steve Bannon person
Masha Bucher person
Jason Calcanis
Michael Wolff person
Noam Chomsky person
Tom Pritzker person
Al Seckel person
Kimbal Musk person
Karyna Shuliak person
Deepak Chopra person
Ken Starr person
Peter Attia person
Jeremy Rubin person
Neri Oxman person
Marvin Minsky person
Lawrence Krauss person
Seth Lloyd person
Boris Nikolic person
Jean Luc Brunel person
Lesley Groff person
Sarah Kellen person
Nadia Marcinkova person
Darren Indyke person
Mark Epstein person
Emad Hanna person
Joscha Bach person
Rich Kahn person
Cecelia Steen
John Amerling person
Sultan Bin Sulayem person
Matthew Hitzik
Peter Mandelson person
groups People directory
74547 threads 209740 messages
arrow_back

Merrill - BAC Step-Up & Biotech

2 messages picture_as_pdf Source PDF
J
James S Pollard May 3, 2016 11:43 AM
To
Richard Kahn
Cc
Darrah, John W - NEW YORK NYMinsky, Julie

Rich,

Below are the details on BAC Step-Up note. I know you mentioned you had bought BAC debt in the past. Let me know if this is of interest.

It looks like that agency offering I mentioned on the phone is all gone. Also the only Preferred deal we have now is on waiting list and we need the HY paperwork on file anyways.

We've also seen the biotech industry have a significant pullback from its July 2015 peak. I attached here a research report that has some of our top picks especially within the larger cap end of the spectrum that have strong baseline businesses. Three of those names also will be reporting later stage clinical date in 2016: AMGN, REGN, and VRTX.

PRICE TALK -
Step-Up Note
Coupon
Schedule:

Current Price Range for Step-Up Schedule:

Levels below are indicative given current market interest rates and are subject to final pricing, but will not be less than the "Minimum Coupon Schedule".

The initial coupon will be 3.00%. We currently expect the second coupon to be no less than 3.50%.

| * | 3.00% until 5/xx/21 |
| | [3.50% -3.65%] until 5/xx/25 |
| | [4.50%-4.65%] until 5/xx/28 |
| | [5.00% -5.15%] until 5/xx/30 |
| | [5.75% -5.90%] until 5/xx/31 |
| | If priced at minimum levels, YTM = 3.753%. |

Minimum Step-Up Coupon Schedule:

The minimum coupon schedule for this Note is as follows and subject to final pricing:

  • 3.00% until 5/xx/21
  • at least 3.00% until 5/xx/25
  • at least 4.00% until 5/xx/28
  • at least 4.50% until 5/xx30
  • at least 5.25% until 5/xx/31
  • If priced at minimum levels, YTM = 3.459%.

Expected

Credit Ratings:

Baal (stable outlook) / BBB+ (stable outlook) / = (stable outlook)

Maturity Date:

5/xx/31

Call Features:

  • 1st Call Date: 5/xx/17

Call Frequency: Semi-annually on each interest payment date.

Distributions:

• 1st Coupon Payment Date: 11/xx/16

• Semi-annually (May and November of each year)

Product Ranking:

Senior Unsecured Notes

Expected Taxation:

Fully taxable as ordinary income

Survivor Option:

NO - This Note does not carry a Survivor option.

Par Amount:

$1000 par

James S. Pollard
Registered Analyst

Team Darrah I Merrill Lynch Wealth Management The Park Avenue Office 200 Park Avenue I 34th Floor I New York I New York 10166

Team Darrah Website

The information set forth herein was from sources, which we believe reliable but we do not guarantee its accuracy neither the information nor an opinion expressed constitutes a solicitation by us of the purchase or sale of any securities or commodities.

The market information contained herein, including, but not limited to, prices, quotes, and statistics, has been obtained from sources that we believe to be reliable, but we do not offer any guarantees as to its accuracy or completeness. Past performance is no guarantee of future results. All information is subject to change without notice. Neither the information nor any opinion expressed constitutes a solicitation for the purchase or sale of any security or other instrument. Merrill Lynch considers your trade confirmations and monthly statements to be the official documentation of all transactions.

Bank of America Corporation (Bank of America) is a financial holding company that, through its subsidiaries and affiliate companies, provides banking and nonbanking financial services.

Merrill Lynch, Pierce, Fenner & Smith Incorporated is a registered broker-dealer, member of SIPC, and wholly owned subsidiary of Bank of America Corporation.

Investment products:

Are not FDIC Insured

Are not Bank Guaranteed

May lose Value

©200= Merrill Lynch, Pierce, Fenner & Smith Incorporated. All rights reserved.

Member Securities Investor Protection Corporation (SIPC).

This message, and any attachments, is for the intended recipient(s) only, may contain information that is privileged, confidential and/or proprietary and subject to important terms and conditions available at http://www.bankofamerica.com/emaildisclaimer. If you are not the intended recipient, please delete this message.

R
Richard Kahn May 3, 2016 5:27 PM
To
jeffrey E.

please advise
thank you

Richard Kahn
HBRK Associates Inc.
575 Lexington =venue 4th Floor
New York, NY 10022

1419 files from the DOJ Epstein case media release. All files are public records from justice.gov.

Built by Truth Tide TV